[Imatinib mesylate as a novel therapeutic drug for systemic rheumatic diseases].
Platelet-derived growth factor (PDGF) is a topic in the pathophysiology of various systemic rheumatic diseases. For example, autoantibody against PDGF receptor was identified in patients with systemic sclerosis. Imatinib mesylate has been well tolerable and widely used for chronic myeloid leukemia and gastrointestinal stromal tomor. Imatinib also inhibits the activation of c-Abl, which is a key downstream molecule of transforming growth factor-beta signaling, and PDGF receptors. Thus, imatinib effectively suppresses the activation and proliferation of fibroblasts, mesangial cells and smooth muscle cells. Therefore, imatinib may overcome the limitation of current therapeutic strategy with corticosteroids and immunosuppressive agents for refractory diseases.
Kameda
Hideto
H
Division of Rheumatology/Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University.
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001549:Benzamides; D006801:Humans; D000068877:Imatinib Mesylate; D017563:Lung Diseases, Interstitial / Q000188:drug therapy; D008181:Lupus Nephritis / Q000188:drug therapy; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D017479:Receptors, Platelet-Derived Growth Factor / Q000187:drug effects; D012216:Rheumatic Diseases / Q000188:drug therapy*; D015398:Signal Transduction / Q000187:drug effects
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D017479:Receptors, Platelet-Derived Growth Factor